The A1 aptamer has the potential to be developed as a biomedical tool for the analysis of PDPN expression and as an effective pharmacological agent in the inhibition of cancer metastasis and various pathological conditions connected with the activation of CELC-2 by PDPN. Here, PDPN is linked to cancer.